Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1)

Ribonucleotide reductase (RNR) is a key target in cancer chemotherapy. The enzyme catalyzes reduction of ribonucleotides to 2′-deoxyribonucleotides and its activity is rate-limiting in de novo synthesis of deoxynucleotide triphosphates (dNTPs). Nucleoside analogues have been investigated as anticanc...

Ausführliche Beschreibung